Compare Organon & Co. Common Stock (OGN) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.55 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 46.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| OGN | VWO | |
|---|---|---|
Market Cap | $3.61B | $168.50B |
Volume | 1,808,049 | 5,654,578 |
Sector | Health | — |
52-Week High | $13.81 | $61.44 |
52-Week Low | $5.70 | $52.42 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VWO trades at $59.68, down 0.08% on the day, with a neutral technical signal. The ETF's performance is influenced by mixed regional exposures, with strength in Taiwan's AI and semiconductor sectors but headwinds from China's economic slowdown. Recent news highlights institutional accumulation and comparisons with other international ETFs, emphasizing its emerging markets focus and 0.06% expense ratio.
The outlook for VWO hinges on emerging market dynamics, particularly tech growth in Taiwan versus China's recovery. Risks include concentrated regional exposure and currency fluctuations. Analyst sentiment is balanced, with technical indicators neutral but institutional interest growing, suggesting cautious optimism for long-term diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
